An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2013
At a glance
- Drugs Motesanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
- 25 Aug 2009 Additional trial locations added as reported by ClinicalTrials.gov.
- 25 Aug 2009 Actual end date (1 Jun 2008) added as reported by ClinicalTrials.gov